📈New Dataset: NR2F1 underlies persistence of residual disease in BRAF-mutant melanoma

By |2026-01-15T21:39:21+00:00January 15, 2026|CCKP, Data Features|

Targeted therapies for melanoma, like BRAF and MEK inhibitors, can shrink tumors but often fail to completely eliminate all cancer cells. A small group [...]